Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences director Fleming John Turman reported the vesting and settlement of restricted stock units into common shares. On January 22, 2026, 1,058 restricted stock units were converted into 1,058 shares of USANA common stock at a price of $0 per share, reflecting the nature of RSUs as equity compensation rather than a market purchase.
After this transaction, Turman directly owned 5,623 shares of USANA common stock and 1,057 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, illustrating a staggered equity incentive structure tied to ongoing service.
USANA Health Sciences director Ding Xia reported stock transactions related to vesting equity awards. On January 22, 2026, 1,058 restricted stock units converted into the same number of USANA common shares at an exercise price of $0.00. These shares came from previously granted equity that vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
On the same day, 392 common shares were disposed of at $22.51 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on the vesting. After these transactions, Ding Xia directly held 6,584 shares of USANA common stock and 1,057 restricted stock units as derivative securities.
Dimensional Fund Advisors LP reported its holdings in USANA Health Sciences Inc. common stock as of 12/31/2025 on an amended Schedule 13G. The firm reported beneficial ownership of 848,452 shares, representing 4.6% of USANA’s outstanding common stock, which is at or below the 5% reporting threshold.
Dimensional reported sole voting power over 829,834 shares and sole dispositive power over the full 848,452 shares, with no shared voting or dispositive power. The filing explains that all securities are actually owned by various funds and accounts it advises (the “Funds”), and that Dimensional may be deemed a beneficial owner solely because it has voting and/or investment power for those Funds.
Dimensional explicitly disclaims beneficial ownership of the shares, stating that the holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control of USANA.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in USANA Health Sciences Inc. common stock. BlackRock reports beneficial ownership of 799,296 shares, representing 4.4% of USANA’s outstanding common stock as of the event date December 31, 2025. It has sole voting power over 788,094 shares and sole dispositive power over 799,296 shares, with no shared voting or dispositive power. The filing states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of USANA. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares through BlackRock.
USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026. The company also provided net sales guidance for its currently expected financial results for the fiscal year ending January 2, 2027. This information is furnished under Items 2.02 and 7.01 and is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Exchange Act and is not incorporated by reference into Securities Act registration statements.
USANA Health Sciences, Inc. reported a leadership transition in which Jim Brown has stepped down as Chief Executive Officer and President, effective January 8, 2026. He will remain with the company in an advisory role for a period at the discretion of the Board of Directors, providing some continuity during the change.
Kevin Guest, age 63, who currently serves as Executive Chairman of the Board and previously served as Chief Executive Officer, will reassume the role of Chief Executive Officer while continuing as Chairman. The company states there is no arrangement or understanding with any other person regarding his selection, and no family or related-party relationships requiring additional disclosure. The Compensation Committee has not yet determined the compensation arrangements for Mr. Brown’s separation or for Mr. Guest’s new role as Chief Executive Officer and expects to decide these shortly, after which an amendment will be filed. The company has issued a press release describing these changes.
USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.
After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.
USANA Health Sciences Inc. (USNA) reported an insider stock transaction by its Chief Information Officer. On 12/10/2025, the officer sold 2,673 shares of common stock in an open market transaction at a price of $20.9506 per share, coded as a sale ("S"). After this transaction, the reporting person held 0 shares of USANA common stock in direct ownership. The filing covers only non-derivative common stock, with no derivative securities reported.
USANA Health Sciences filed a notice under Rule 144 for a planned sale of restricted common stock. The filing covers 2,673 shares of common stock, with an aggregate market value of $56,000.95, to be sold through Morgan Stanley Smith Barney LLC on the NYSE. The issuer had 18,280,857 shares of common stock outstanding. The shares were acquired from the issuer as restricted stock in several transactions dated between February 6, 2025 and July 25, 2025. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
USANA Health Sciences (USNA) Form 4: A director reported an open-market sale of common stock. On 11/10/2025, the director sold 2,000 shares (transaction code S) at a price of $19.21 per share. Following this transaction, the director beneficially owns 5,986 shares, held directly.